The effect of ivermectin on the viral load and culture viability in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial
et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.07.003 (results 2/12/21), NCT04429711 (history)
, The effect of ivermectin on the viral load and culture viability in early treatment of non-hospitalized.., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.07.003 (results 2/12/21), NCT04429711
Double blind RCT for mild-moderate COVID-19 outpatients in Israel showing significantly faster reduction in viral load with treatment, and lower hospitalization with treatment. The one treatment hospitalization was a few hours after treatment and the patient improved and was discharged quickly. Authors also examine culture viability on days 2-6, with 13% positive in the ivermectin group vs. 48% in the control group. There were no safety issues. Ivermectin was taken one hour before a meal. Sheba IRB-7156/20. NCT04429711 (history).This is the 17th of 46 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.00000014.This is the 37th of 97 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 2 sextillion).
|
risk of hospitalization, 70.2% lower, RR 0.30, p = 0.34, treatment 1 of 47 (2.1%), control 3 of 42 (7.1%), NNT 20.
|
|
risk of no viral clearance, 61.6% lower, RR 0.38, p = 0.02, treatment 8 of 47 (17.0%), control 17 of 42 (40.5%), NNT 4.3, adjusted per study, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, Ct>30, multivariable, day 8.
|
|
risk of no viral clearance, 39.0% lower, RR 0.61, p = 0.09, treatment 13 of 47 (27.7%), control 21 of 42 (50.0%), NNT 4.5, adjusted per study, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, Ct>30, multivariable, day 6, primary outcome.
|
|
risk of no viral clearance, 73.0% lower, RR 0.27, p = 0.008, treatment 3 of 23 (13.0%), control 14 of 29 (48.3%), NNT 2.8, culture viability.
|
|
risk of no viral clearance, 70.2% lower, RR 0.30, p = 0.14, treatment 2 of 47 (4.3%), control 6 of 42 (14.3%), NNT 10.0, non-infectious samples (Ct>30 or non-viable culture), day 10.
|
|
risk of no viral clearance, 82.1% lower, RR 0.18, p = 0.01, treatment 2 of 47 (4.3%), control 10 of 42 (23.8%), NNT 5.1, non-infectious samples (Ct>30 or non-viable culture), day 8.
|
|
risk of no viral clearance, 75.6% lower, RR 0.24, p = 0.02, treatment 3 of 47 (6.4%), control 11 of 42 (26.2%), NNT 5.0, non-infectious samples (Ct>30 or non-viable culture), day 6.
|
|
risk of no viral clearance, 65.1% lower, RR 0.35, p = 0.05, treatment 4 of 28 (14.3%), control 9 of 22 (40.9%), NNT 3.8, non-infectious samples (Ct>30 or non-viable culture), day 4.
|
|
risk of no viral clearance, 51.9% lower, RR 0.48, p = 0.08, treatment 7 of 47 (14.9%), control 13 of 42 (31.0%), NNT 6.2, Ct>30, day 10.
|
|
risk of no viral clearance, 57.9% lower, RR 0.42, p = 0.02, treatment 8 of 47 (17.0%), control 17 of 42 (40.5%), NNT 4.3, Ct>30, day 8.
|
|
risk of no viral clearance, 44.7% lower, RR 0.55, p = 0.049, treatment 13 of 47 (27.7%), control 21 of 42 (50.0%), NNT 4.5, Ct>30, day 6.
|
|
risk of no viral clearance, 31.9% lower, RR 0.68, p = 0.16, treatment 13 of 28 (46.4%), control 15 of 22 (68.2%), NNT 4.6, Ct>30, day 4.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Biber et al., 12 Feb 2021, Double Blind Randomized Controlled Trial, placebo-controlled, Israel, peer-reviewed, 10 authors, average treatment delay 4.0 days, dosage 12mg days 1-3, 15mg for patients ≥70kg, trial NCT04429711 (history).
Contact:
elischwa@tauex.tau.ac.il.
The effect of ivermectin on the viral load and culture viability in early treatment of nonhospitalized patients with mild COVID-19 – a double-blind, randomized placebo-controlled trial
International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.07.003
The effect of ivermectin on the viral load and culture viability in early treatment of non-hospitalized patients with mild COVID-19 -A double-blind, randomized placebo-controlled trial,
☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:
References
Basso, Aita, Navaglia, Franchin, Fioretto et al., SARS-CoV-2 RNA identification in nasopharyngeal swabs: issues in pre-analytics, Clin Chem Lab Med, doi:10.1515/cclm-2020-0749
Biancofiore, Mirijello, Puteo, Di Viesti, Labonia et al., Remdesivir significantly reduces SARS-CoV-2 viral load on nasopharyngeal swabs in hospitalized patients with COVID-19: A retrospective case-control study, Journal of Medical Virology, doi:10.1002/jmv.27598
Bray, Rayner, Noël, Jans, Wagstaff, Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses, Antiviral Res, doi:10.1016/j.antiviral.2020.104805
Brown, Chand, Andrews, Auckland, Beshir, Snapshot PCR surveillance for SARS-CoV-2 in hospital staff in England, J Infect, doi:10.1016/j.jinf.2020.06.069
Bryant, Lawrie, Dowswell, Fordham, Mitchell et al., Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines, Am J Ther, doi:10.1097/MJT.0000000000001402
Bullard, Dust, Funk, Strong, Alexander et al., Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples, Clin Infect Dis, doi:10.1093/cid/ciaa638
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res, doi:10.1016/j.antiviral.2020.104787
Caly, Wagstaff, Jans, Nuclear trafficking of proteins from RNA viruses: potential target for antivirals?, Antiviral Res, doi:10.1016/j.antiviral.2012.06.008
Carroll, Mcnamara, Comparison and correlation of commercial SARS-CoV-2 real-time-PCR assays, Ireland, Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, doi:10.2807/1560-7917.ES.2021.26.6.2002079
Choudhury, Das, Patra, Bhattacharya, Ghosh et al., Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in silico approach, Future Virology, doi:10.2217/fvl-2020-0342
Eweas, Alhossary, As, Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2, Frontiers in Microbiology, doi:10.3389/fmicb.2020.592908
Fischer, Eron, Holman, Cohen, Fang et al., A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus, Sci Transl Med, doi:10.1126/scitranslmed.abl7430
Gilad, Oran, Itai, Eli, Evaluation of the relationship between quantitative PCR results and cell culturing of SARS2-CoV with respect to symptoms onset and Viral load -a systematic review, MedRxiv, doi:10.1101/2021.08.23.21262162
Götz, Magar, Dornfeld, Giese, Pohlmann et al., Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import, Sci Rep, doi:10.1038/srep23138
Hill, Mirchandani, Pilkington, Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud, Open Forum Infect Dis, doi:10.1093/ofid/ofab645
Laing, Devaney, Ivermectin -Old Drug, New Tricks?, Trends Parasitol, doi:10.1016/j.pt.2017.02.004
Lefferts, Blake, Bruden, Hagen, Hodges et al., Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication, MMWR Morb Mortal Wkly Rep, doi:10.15585/mmwr.mm7108a3
Mehta, Mcauley, Brown, Sanchez, Tattersall et al., COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet, doi:10.1016/S0140-6736(20)30628-0
Padhy, Mohanty, Das, Meher, Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis, Journal of Pharmacy & Pharmaceutical Sciences : A Publication of the Canadian Society for Pharmaceutical Sciences, doi:10.18433/jpps31457
Poopalasingam, Korenkov, Ashurov, Strobel, Fish et al., Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19, New Microbes and New Infections, doi:10.2139/ssrn.4000128
Schwartz, Does Ivermectin have a place in the treatment of mild Covid-19? New Microbes and New Infections
Schwartz, Does ivermectin have a place in the treatment of mild Covid-19?, New Microbes and New Infections, doi:10.1016/j.nmni.2022.100985
Siedner, Tay, Myf, Fraser, Chan et al., Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin, Open Forum Infectious Diseases, doi:10.1093/ofid/ofab318
Wagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem J, doi:10.1042/BJ20120150
Wu, Mcgoogan, Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention, JAMA, doi:10.1001/jama.2020.2648
Wölfel, Corman, Guggemos, Seilmaier, Zange et al., Virological assessment of hospitalized patients with COVID-2019, Nature, doi:10.1038/s41586-020-2196-x
Zaidi, Dehgani-Mobaraki, The mechanisms of action of ivermectin against SARS-CoV-2-an extensive review, J Antibiot, doi:10.1038/s41429-021-00491-6
Zein, Sulistiyana, Raffaelo, Pranata, Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials, Diabetes Metab Syndr n.d, doi:10.1016/j.dsx.2021.102186
Zhang, Song, Ci, Ju, Li, Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice, Inflamm Res, doi:10.1007/s00011-008-8007-8
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.